ID4 is frequently downregulated and partially hypermethylated in prostate cancer

World Journal of Urology

Volumn 30, Issue 3, 2012, Pages 319-325

  Vinarskaja, Anna ^a   Goering, Wolfgang ^a   Ingenwerth, Marc ^a   Schulz, Wolfgang A ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

DNA methylation; Methylation biomarkers; Prostate cancer prognosis; Tumor suppressor

Indexed keywords

DNA; ID4 PROTEIN, HUMAN; INHIBITOR OF DIFFERENTIATION PROTEIN; MESSENGER RNA;

AGED; ARTICLE; CELL CULTURE; COMPARATIVE STUDY; CYTOLOGY; DNA METHYLATION; DOWN REGULATION; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHYSIOLOGY; PROSTATE; PROSTATE TUMOR; PROSTATECTOMY; TUMOR CELL LINE;

AGED; BASE SEQUENCE; CELL LINE, TUMOR; CELLS, CULTURED; DNA METHYLATION; DNA, NEOPLASM; DOWN-REGULATION; HUMANS; INHIBITOR OF DIFFERENTIATION PROTEINS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RNA, MESSENGER;

EID: 84861628256     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-011-0750-8     Document Type: Article

References (30)

1. Laird PW (2003) The power and the promise of DNA methylation markers. Nat Rev Cancer 3: 253-266.
2. Schulz WA, Hoffmann MJ (2009) Epigenetic mechanisms in the biology of prostate cancer. Semin Cancer Biol 19: 172-180.
3. Hoque MO (2009) DNA methylation changes in prostate cancer: current developments and future clinical implementation. Expert Rev Mol Diagn 9: 243-257.
4. Payne SR, Serth J, Schostak M, Kamradt J, Strauss A, Thelen P, Model F, Day JK, Liebenberg V, Morotti A, Yamamura S, Lograsso J, Sledziewski A, Semjonow A (2009) DNA methylation biomarkers of prostate cancer: confirmation of candidates and evidence urine is the most sensitive body fluid for non-invasive detection. Prostate 69: 1257-1269.
5. Candiloro IL, Mikeska T, Dobrovic A (2011) Assessing combined methylation-sensitive high resolution melting and pyrosequencing for the analysis of heterogeneous DNA methylation. Epigenetics 6: 500-507.
6. Shames DS, Minna JD, Gazdar AF (2007) Methods for detecting DNA methylation in tumors: from bench to bedside. Cancer Lett 251: 187-198.
7. Lasorella A, Uo T, Iavarone A (2001) Id proteins at the cross-road of development and cancer. Oncogene 20: 8326-8333.
8. Zebedee Z, Hara E (2001) Id proteins in cell cycle control and cellular senescence. Oncogene 20: 8317-8325.
9. Dell'Orso S, Ganci F, Strano S, Blandino G, Fontemaggi G (2010) ID4: a new player in the cancer arena. Oncotarget 1: 48-58.
10. Wu Q, Hoffmann MJ, Hartmann FH, Schulz WA (2005) Amplification and overexpression of the ID4 gene at 6p22. 3 in bladder cancer. Mol Cancer 4: 16.
11. Chan AS, Tsui WY, Chen X, Chu KM, Chan TL, Chan AS, Li R, So S, Yuen ST, Leung SY (2003) Downregulation of ID4 by promoter hypermethylation in gastric adenocarcinoma. Oncogene 22: 6946-6953.
12. Chen SS, Claus R, Lucas DM, Yu L, Qian J, Ruppert AS, West DA, Williams KE, Johnson AJ, Sablitzky F, Plass C, Byrd JC (2011) Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL. Blood 117: 862-871.
13. Noetzel E, Veeck J, Niederacher D, Galm O, Horn F, Hartmann A, Knüchel R, Dahl E (2008) Promoter methylation-associated loss of ID4 expression is a marker of tumour recurrence in human breast cancer. BMC Cancer 8: 154.
14. Smith E, De Young NJ, Pavey SJ, Hayward NK, Nancarrow DJ, Whiteman DC, Smithers BM, Ruszkiewicz AR, Clouston AD, Gotley DC, Devitt PG, Jamieson GG, Drew PA (2008) Similarity of aberrant DNA methylation in Barrett's esophagus and esophageal adenocarcinoma. Mol Cancer 7: 75.
15. Umetani N, Takeuchi H, Fujimoto A, Shinozaki M, Bilchik AJ, Hoon DS (2004) Epigenetic inactivation of ID4 in colorectal carcinomas correlates with poor differentiation and unfavorable prognosis. Clin Cancer Res 10: 7475-7483.
16. Wang H, Wang XQ, Xu XP, Lin GW (2010) ID4 methylation predicts high risk of leukemic transformation in patients with myelodysplastic syndrome. Leuk Res 34: 598-604.
17. Coppe JP, Itahana Y, Moore DH, Bennington JL, Desprez PY (2004) Id-1 and Id-2 proteins as molecular markers for human prostate cancer progression. Clin Cancer Res 10: 2044-2051.
18. Ling MT, Wang X, Ouyang XS, Xu K, Tsao SW, Wong YC (2003) Id-1 expression promotes cell survival through activation of NF-kappaB signalling pathway in prostate cancer cells. Oncogene 22: 4498-4508.
19. Perk J, Gil-Bazo I, Chin Y, de Candia P, Chen JJ, Zhao Y, Chao S, Cheong W, Ke Y, Al-Ahmadie H, Gerald WL, Brogi E, Benezra R (2006) Reassessment of ID1 protein expression in human mammary, prostate, and bladder cancers using a monospecific rabbit monoclonal anti-ID1 antibody. Cancer Res 66: 10870-10877.
20. Yuen HF, Chua CW, Chan YP, Wong YC, Wang X, Chan KW (2006) Id proteins expression in prostate cancer: high-level expression of Id-4 in primary prostate cancer is associated with development of metastases. Mod Pathol 19: 931-941.
21. Carey JP, Asirvatham AJ, Galm O, Ghogomu TA, Chaudhary J (2009) Inhibitor of differentiation 4 (Id4) is a potential tumor suppressor in prostate cancer. BMC Cancer 9: 173.
22. Schulz WA, Alexa A, Jung V, Hader C, Hoffmann MJ, Yamanaka M, Fritzsche S, Wlazlinski A, Müller M, Lengauer T, Engers R, Florl AR, Wullich B, Rahnenführer J (2007) Factor interaction analysis for chromosome 8 and DNA methylation alterations highlights innate immune response suppression and cytoskeletal changes in prostate cancer. Mol Cancer 6: 14.
23. Asirvatham AJ, Schmidt MA, Chaudhary J (2006) Non-redundant inhibitor of differentiation (Id) gene expression and function in human prostate epithelial cells. Prostate 66: 921-935.
24. McCabe MT, Brandes JC, Vertino PM (2009) Cancer DNA methylation: molecular mechanisms and clinical implications. Clin Cancer Res 15: 3927-3937.
25. Mehrotra J, Varde S, Wang H, Chiu H, Vargo J, Gray K, Nagle RB, Neri JR, Mazumder A (2008) Quantitative, spatial resolution of the epigenetic field effect in prostate cancer. Prostate 68: 152-160.
26. Steiner I, Jung K, Schatz P, Horns T, Wittschieber D, Lein M, Dietel M, Erbersdobler A (2010) Gene promoter methylation and its potential relevance in early prostate cancer diagnosis. Pathobiology 77: 260-266.
27. Bhusari S, Yang B, Kueck J, Huang W, Jarrard DF (2011) Insulin-like growth factor-2 (IGF2) loss of imprinting marks a field defect within human prostates containing cancer. Prostate (in press).
28. Haaland CM, Heaphy CM, Butler KS, Fischer EG, Griffith JK, Bisoffi M (2009) Differential gene expression in tumor adjacent histologically normal prostatic tissue indicates field cancerization. Int J Oncol 35: 537-546.
29. Hornstein M, Hoffmann MJ, Alexa A, Yamanaka M, Müller M, Jung V, Rahnenführer J, Schulz WA (2008) Protein phosphatase and TRAIL receptor genes as new candidate tumor genes on chromosome 8p in prostate cancer. Cancer Genomics Proteomics 5: 123-136.
30. Nonn L, Ananthanarayanan V, Gann PH (2009) Evidence for field cancerization of the prostate. Prostate 69: 1470-1479.